177Lu-DOTATATE治疗后实验室肝脏参数的改善:肿瘤参考中心的队列
该回顾性观察性单中心研究分析了2011年1月至2021年12月接受1至4个周期7.4 GBq(200 mCi)177Lu-DOTATATE治疗的110例患者,评估治疗前后肝脏、胆汁淤积、肾脏及骨髓功能实验室指标变化。结果显示一般人群中ALP(P=0.013)和GGT(P<0.001)显著降低,高肝脏病变体积患者ALT显著降低(P=0.016),低肝脏病变体积患者GGT显著降低(P=0.013),所有骨髓功能参数在所有人群亚组中均显著下降。
要点
- 110例接受177Lu-DOTATATE治疗患者中,ALP(P=0.013)和GGT(P<0.001)显著降低。
- 高肝脏病变体积患者ALT显著降低(P=0.016),低肝脏病变体积患者GGT显著降低(P=0.013)。
- 所有骨髓功能参数在所有人群亚组中均显著下降。
核心结论
- 接受177Lu-DOTATATE治疗的患者肝功能和胆汁淤积参数显著改善,骨髓功能持续下降,即使在存在晚期肝病的情况下也是如此。
研究设计与样本
- 回顾性观察性单中心研究,纳入2011年1月至2021年12月接受1至4个周期7.4 GBq(200 mCi)177Lu-DOTATATE治疗的110例患者,每个周期前后进行血液检查。
主要发现
- 在一般人群(n=110)中,ALP(P=0.013)和GGT(P<0.001)显示统计学显著降低。
- 高肝脏病变体积患者ALT显示统计学显著降低(P=0.016),低肝脏病变体积患者GGT显示统计学显著降低(P=0.013)。
- 所有骨髓功能参数在所有人群亚组中均显示统计学显著下降。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Well-differentiated neuroendocrine neoplasms (NETs) overexpress the somatostatin receptor, which is the target for the peptide receptor radionuclide therapy (PRRT). NETs have a slow growth rate and can metastasize to liver, bone, and lungs. In NETs patients, liver metastasis is an important prognostic marker because liver failure is one of the most common causes of death in this population. In this regard, we aimed to describe the changes in laboratorial parameters in patients submitted to PRRT with 177 Lu-DOTATATE, focusing on hepatic parameters. PATIENTS AND METHODS: One hundred ten patients treated with 1 to 4 cycles of 7.4 GBq (200 mCi) of 177 Lu-DOTATATE from January 2011 to December 2021 were analyzed in this retrospective observational single-center study. Patients were submitted to blood tests before and after each cycle of PRRT. Laboratory measurements were collected to assess liver function, cholestasis, kidney, and bone marrow function. RESULTS: In the general population (n = 110), ALP ( P = 0.013) and GGT ( P < 0.001) showed a statistically significant reduction. Patients with high liver disease volume showed a statistically significant reduction in ALT ( P = 0.016), whereas patients with low liver disease volume showed a statistically significant reduction in GGT ( P = 0.013). All parameters for bone marrow function showed a statistically significant decrease in all population subsets. CONCLUSIONS: Patients treated with 177 Lu-DOTATATE showed a significant improvement in liver function and cholestasis parameters, and a consistent decrease in bone marrow function, even in the presence of advanced liver disease.
引用
- Dos Santos Soares F, de Carvalho JR, de Lima BAM, et al. Improvement of Laboratory Hepatic Parameters After Treatment With 177 Lu-DOTATATE : Cohort in an Oncology Reference Center. Clin Nucl Med. 2024. PMID: 39087646. doi:10.1097/RLU.0000000000005375
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。